IKT – inhibikase therapeutics, inc. (US:NASDAQ)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

YTD

1 Day

IKT

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

12/11

09:55 am

ikt

Rating for IKT

Report

Rating for IKT

Report

12/11

08:43 am

ikt

Inhibikase Therapeutics (NYSE:IKT) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $4.00 price target on the stock.

Medium Report

Inhibikase Therapeutics (NYSE:IKT) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $4.00 price target on the stock.

Report

12/11

07:57 am

ikt

Inhibikase Therapeutics initiated with an Overweight at Cantor Fitzgerald

Medium Report

Inhibikase Therapeutics initiated with an Overweight at Cantor Fitzgerald

Report

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.